News NetraMark Holdings Inc.

Stocks

AIAI

CA64119M1059

Software

Market Closed - Toronto S.E. 22:33:04 30/10/2026 +03			5-day change	1st Jan Change
0.5900 ^CAD	+1.72%		+13.46%	-46.36%

09-10	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
09-01	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI

All News

Mentions Relevance

10-08	NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright's AI-Based Drug Discovery and Development Conference	AQ
10-07	NetraMark Founder Dr. Joseph Geraci to Participate in H.C. Wainwright’s AI-Based Drug Discovery and Development Conference	AQ
09-10	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
09-10	Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models	AQ
09-08	NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor	AQ
09-01	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI
09-01	NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier	AQ
08-27	NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	AQ
08-20	NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High	AQ
08-14	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
07-13	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness	AQ
07-09	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data	MT
07-09	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	CI
07-09	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	AQ
06-29	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
06-29	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
06-29	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
06-09	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
05-25	Upcoming Meeting Dates - May 25, 2026	NE
05-20	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
05-15	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
05-15	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
05-07	NetraMark Announces Change To Board Of Directors	AQ
05-07	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026	CI
05-05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE